Holen Sie sich die Stockscreener-App
5.82
5.56%
0.24
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results - TipRanks
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU market drives stock outlook - Investing.com India
Jasper releases new data on briquilimab from SPOTLIGHT trial - The Pharma Letter
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | - GuruFocus
Jasper Therapeutics Reports Positive Data from 180mg Cohort - GlobeNewswire
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized - Investing.com Canada
Cantor Fitzgerald Weighs in on JSPR FY2026 Earnings - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
Wellington Management Group LLP Boosts Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Trend Tracker for (JSPR) - news.stocktradersdaily.com
Is Monster Beverage Stock Outperforming the S&P 500? - The Globe and Mail
Jane Street Group LLC Sells 2,502 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Warren Buffett Is Ready to Invest $100 Billion in a Stock That Meets These 3 Criteria - The Globe and Mail
Jasper Therapeutics Announces Acceptance of Four Abstracts for Presentation at EAACI Congress 2025 - Nasdaq
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Breakthrough Clinical Data: Jasper's Briquilimab Shows Promise in Treating Resistant Urticaria Cases - Stock Titan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - Yahoo Finance
Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market - TipRanks
Bank of America Corp DE Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Northern Trust Corp Trims Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Market Analysis: May 26th, 2025 - The Globe and Mail
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment - Investing.com Canada
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment By Investing.com - Investing.com South Africa
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential - Insider Monkey
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stake Lifted by Deutsche Bank AG - Defense World
Spotify Stock's Rally Still Has Legs To Run Higher - The Globe and Mail
Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR - Defense World
Oppenheimer Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $65.00 - Defense World
Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News - GuruFocus
(JSPR) Trading Report - news.stocktradersdaily.com
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
William Blair Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst - Defense World
Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating - marketscreener.com
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) - GuruFocus
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus
Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Nasdaq
Jasper Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus
JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News - GuruFocus
Jasper (JSPR) Advances Briquilimab with Promising Trial Results - GuruFocus
UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating - marketscreener.com
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Tuesday - Defense World
Wells Fargo & Company MN Purchases 3,828 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $62.50 - Defense World
JPMorgan Chase & Co. Sells 11,226 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
(JSPR) Trading Advice - news.stocktradersdaily.com
JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Global Fanconi Anemia Market Insights: Jasper Therapeutics, - openPR.com
2.97%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):